Anzeige
Erschienen in:
01.10.2015 | Original Article – Clinical Oncology
Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis
Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2015
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.
Methods
A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.
Results
Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30–3.78) and DFS (HR 2.63; 95 % CI 1.10–6.29) and increased RR (OR 3.29; 95 % CI 1.67–6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49–1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66–3.57) and DFS (HR 4.27; 95 % CI 1.15–15.78), increased RR (OR 3.11; 95 % CI 2.01–4.81), and decreased CRR (OR 0.42; 95 % CI 0.25–0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38–2.19) and DFS (HR 2.38; 95 % CI 1.87–3.02), increased RR (OR 5.19; 95 % CI 2.84–9.48), and decreased CRR (OR 0.62; 95 % CI 0.41–0.96).
Conclusions
This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.